REMISE study: REMnant biospecimen Investigation in SEpsis

REMISE 研究：SEpsis 中的 REMnant 生物样本研究

基本信息

批准号：
10352753
负责人：
Christopher Warren Seymour
金额：
$ 22.6万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-01-01 至 2023-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10352753
关键词：
Aging American Award Biological Markers Biological Specimen Banks Biology Blood Case Mixes Cellular biology Cessation of life Clinical Clinical Data Collaborations Collection Communities Community Hospitals Computational Biology Critical Illness Data Disease Electronic Health Record Enrollment Etiology Evaluation Eye Functional disorder Funding Future Generations Heterogeneity Hospitals Human Immune response Immunology Infection Inflammation Informed Consent Infrastructure Integrated Health Care Systems Investigation Laboratories Life Link Lipids Machine Learning Measurement Medicine Microbiology Modeling National Institute of General Medical Sciences Organ Outcome Pathology Patients Phase Phenotype Pilot Projects Plasma Population Proteomics Protocols documentation Research Research Infrastructure Role Sampling Schedule Sepsis Site Specific qualifier value Specimen Supervision Systems Biology Time Tissues Translational Research Trauma patient Universities biobank clinical phenotype cost genomic biomarker improved outcome injured innovation lipidomics metabolomics multiple omics pathogen pathogen genomics personalized strategies prospective randomized trial repository response septic patients severe injury small molecule targeted treatment translational study treatment response wasting

项目摘要

PROJECT SUMMARY / ABSTRACT Almost 2 million Americans are hospitalized with sepsis each year, and nearly one in five don’t survive. Most efforts to reduce sepsis deaths begin with the premise that patients are largely similar, and that targeting therapeutics to a single mechanism will improve outcomes. But sepsis patients differ in pathogen, biology, outcomes, and are proposed to have treatment responsive endotypes. Greater study of sepsis endotypes has been limited by costly infrastructure and biospecimen collection that is not scalable. To solve this challenge, we will use a clinical remnant biorepository to understand feasibility, integrity, and scientific value for mechanistic sepsis research. We will evaluate traditional biomarkers, quantitative proteomics, metabolomics, lipidomics, and pathogen genomic sequencing in remnant specimens and graduate successful data “layers” to a scaled, community hospital repository. This cross-cutting project will be supervised by an external advisory board with expertise in inflammation, immunology, computational and systems biology, and laboratory and pathology medicine. This approach will further develop our NIGMS-funded clinical-translational laboratory, creating new hypotheses from a diverse, academic and community hospital remnant biorepository acquired from an endotype-enriched population of sepsis patients. Finally, we will further integrate these data with multi-omics read-outs in severely injured trauma patients to explore shared/unshared mechanisms in critical illness.

项目概要/摘要每年有近 200 万美国人因脓毒症住院，其中近五分之一大多数减少脓毒症死亡的努力都是以患者无法生存为前提的。很大程度上相似，并且针对单一机制的治疗将会改善但脓毒症患者的病原体、生物学、结果各不相同，因此提出了建议。对脓毒症内型进行了更深入的研究。受限于昂贵的基础设施和不可扩展的生物样本收集。针对这一挑战，我们将使用临床残留生物样本库来了解可行性，我们将评估传统脓毒症研究的完整性和科学价值。生物标志物、定量蛋白质组学、代谢组学、脂质组学和病原体基因组学对剩余样本进行测序，并将成功的数据“层”分级为按比例缩放的、该跨领域项目将由社区医院存储库监督。外部顾问委员会在炎症、免疫学、计算和系统生物学、实验室和病理学医学将进一步发展。发展我们的 NIGMS 资助的临床转化实验室，创造新的假设来自多样化的学术和社区医院残余生物储存库最后，我们将进一步整合脓毒症患者的内型丰富的人群。这些数据通过重伤创伤患者的多组学读数来探索危重疾病的共享/非共享机制。